Cytovance Biologics Inc. Appoints Don Wuchterl As Chief Operating Officer

Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing company, announced the promotion of Donald Wuchterl to Chief Operating Officer. In this new capacity, Mr. Wuchterl will oversee Cytovance's Research & Development Services, Manufacturing & Warehouse, Facilities, Engineering, and Program Management functions. Mr. Wuchterl joined Cytovance in July of 2012 as the Sr. Vice President of Manufacturing Operations. In that brief time, he's made significant contributions to Cytovance, demonstrating a commitment to improving systems, facilities, and personnel.
Mr. Wuchterl has built up an accomplished and empowered team that significantly contributed to Cytovance's doubling in size in the last two years. In addition to organizational improvements, Mr. Wuchterl also plays a major leadership role to enabling Cytovance's continued growth and expansion. This includes the construction and qualification/validation of several new production suites as well as a new Greenfield Manufacturing and GMP Warehousing facility that will greatly increase Cytovance's scale, service offerings, and technical capabilities. "I have had the distinct pleasure of knowing Don for many years and feel he is the ideal candidate for this position. His knowledge and experience with both clinical and commercial biologics manufacturing, along with his years of working in the design and validation of biologics facilities makes him an invaluable asset to Cytovance's Leadership team," said CEO Darren Head.

Donald Wuchterl has over 22 years of experience manufacturing clinical and commercial GMP products including biologics, small molecules, and cellular immunotherapies. Mr. Wuchterl has extensive experience in the design, validation, licensure, and operation of these facilities. Prior to joining Cytovance, Mr. Wuchterl was Director of Manufacturing at Dendreon, responsible for the construction, start-up, and operation of their cellular immunotherapy manufacturing facility in Union City, Georgia. Previous to Dendreon, Mr. Wuchterl held the position of Director of Manufacturing at Shire, Human Genetic Therapies where he had General Manager Responsibilities for the end user design and start-up of Shire's Lexington, Massachusetts facility expanding their enzyme replacement therapy manufacturing capacity. Previous to Shire, Mr. Wuchterl held several positions of increasing responsibility with Amgen at their facilities in Colorado, Rhode Island, and Cork Ireland. Additionally, Mr. Wuchterl worked for Biogen Idec and Roche early in his career. Mr. Wuchterl holds a Bachelor's of Science degree in Business Administration from Colorado Technical University.

"I am honored to be recognized by Darren Head, President and CEO of Cytovance, and the Board of Directors in expanding my role on Cytovance's Executive Leadership Team," said Donald Wuchterl. "I have the benefit of working with an incredibly talented organization with standout performers at every level. I look forward to working with our executive team, the operations leadership team, the quality unit, and our gifted employees as we continue into the next phase of the company's evolution. Combining all of the 'execution' facets of the Cytovance organization under one umbrella will improve performance, reduce silo effects, and ultimately provide a better customer experience."


MEDIA CONTACT
Cheryl Tuck
Marketing Communications Manager
Email Contact
405.319.8310

Suggested Articles

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

As the White House continues its push for the benefits of "right to try," the first CRO associated with the law has come onto the stage.

Amplyx revealed early data for its lead program in candidemia and licensed a phase 2-ready program for BK virus infection from Novartis.